OBJECTIVE: To evaluate COVID-19 vaccine breakthrough infections among immunocompromised (IC) individuals. METHODS: Individuals vaccinated with BNT162b2 were selected from the US HealthVerity database (10 December 2020 to 8 July 2021). COVID-19 vaccine breakthrough infections were examined in fully vaccinated (≥14 days after 2nd dose) IC individuals (IC cohort), 12 mutually exclusive IC condition groups, and a non-IC cohort. IC conditions were identified using an algorithm based on diagnosis codes and immunosuppressive (IS) medication usage. RESULTS: Of 1,277,747 individuals ≥16 years of age who received 2 BNT162b2 doses, 225,796 (17.7%) were identified as IC (median age: 58 years; 56.3% female). The most prevalent IC conditions were solid malignancy (32.0%), kidney disease (19.5%), and rheumatologic/inflammatory conditions (16.7%). Among the fully vaccinated IC and non-IC cohorts, a total of 978 breakthrough infections were observed during the study period; 124 (12.7%) resulted in hospitalization and 2 (0.2%) were inpatient deaths. IC individuals accounted for 38.2% (N = 374) of all breakthrough infections, 59.7% (N = 74) of all hospitalizations, and 100% (N = 2) of inpatient deaths. The proportion with breakthrough infections was 3 times higher in the IC cohort compared to the non-IC cohort (N = 374 [0.18%] vs. N = 604 [0.06%]; unadjusted incidence rates were 0.89 and 0.34 per 100 person-years, respectively. Organ transplant recipients had the highest incidence rate; those with >1 IC condition, antimetabolite usage, primary immunodeficiencies, and hematologic malignancies also had higher incidence rates compared to the overall IC cohort. Incidence rates in older (≥65 years old) IC individuals were generally higher versus younger IC individuals (<65). LIMITATIONS: This retrospective analysis relied on coding accuracy and had limited capture of COVID-19 vaccine receipt. CONCLUSIONS: COVID-19 vaccine breakthrough infections are rare but are more common and severe in IC individuals. The findings from this large study support the FDA authorization and CDC recommendations to offer a 3rd vaccine dose to increase protection among IC individuals.
OBJECTIVE: To evaluate COVID-19 vaccine breakthrough infections among immunocompromised (IC) individuals. METHODS: Individuals vaccinated with BNT162b2 were selected from the US HealthVerity database (10 December 2020 to 8 July 2021). COVID-19 vaccine breakthrough infections were examined in fully vaccinated (≥14 days after 2nd dose) IC individuals (IC cohort), 12 mutually exclusive IC condition groups, and a non-IC cohort. IC conditions were identified using an algorithm based on diagnosis codes and immunosuppressive (IS) medication usage. RESULTS: Of 1,277,747 individuals ≥16 years of age who received 2 BNT162b2 doses, 225,796 (17.7%) were identified as IC (median age: 58 years; 56.3% female). The most prevalent IC conditions were solid malignancy (32.0%), kidney disease (19.5%), and rheumatologic/inflammatory conditions (16.7%). Among the fully vaccinated IC and non-IC cohorts, a total of 978 breakthrough infections were observed during the study period; 124 (12.7%) resulted in hospitalization and 2 (0.2%) were inpatient deaths. IC individuals accounted for 38.2% (N = 374) of all breakthrough infections, 59.7% (N = 74) of all hospitalizations, and 100% (N = 2) of inpatient deaths. The proportion with breakthrough infections was 3 times higher in the IC cohort compared to the non-IC cohort (N = 374 [0.18%] vs. N = 604 [0.06%]; unadjusted incidence rates were 0.89 and 0.34 per 100 person-years, respectively. Organ transplant recipients had the highest incidence rate; those with >1 IC condition, antimetabolite usage, primary immunodeficiencies, and hematologic malignancies also had higher incidence rates compared to the overall IC cohort. Incidence rates in older (≥65 years old) IC individuals were generally higher versus younger IC individuals (<65). LIMITATIONS: This retrospective analysis relied on coding accuracy and had limited capture of COVID-19 vaccine receipt. CONCLUSIONS: COVID-19 vaccine breakthrough infections are rare but are more common and severe in IC individuals. The findings from this large study support the FDA authorization and CDC recommendations to offer a 3rd vaccine dose to increase protection among IC individuals.
Authors: Jose Rafael Teran-Tinedo; Jesus Gonzalez-Rubio; Alberto Najera; Andrea Castany-Faro; Maria de Las Nieves Contreras; Isabel Maria Garcia; Lourdes Lopez-Mellado; Miguel Lorente-Gonzalez; Patricia Perez-Garvin; Galaxia Sacristan-Crespo; Miguel Suarez-Ortiz; Juan D Navarro-Lopez; Lydia Jimenez-Diaz; Pedro Landete Journal: EClinicalMedicine Date: 2022-05-20
Authors: Elizabeth M Garry; Andrew R Weckstein; Kenneth Quinto; Marie C Bradley; Tamar Lasky; Aloka Chakravarty; Sandy Leonard; Sarah E Vititoe; Imaani J Easthausen; Jeremy A Rassen; Nicolle M Gatto Journal: Pharmacoepidemiol Drug Saf Date: 2022-05-09 Impact factor: 2.732
Authors: Britta Maurer; Matthias B Moor; Daniel Sidler; Alexander Born; Simeon Schietzel; Michael P Horn; Daniel Aeberli; Jennifer Amsler; Burkhard Möller; Linet M Njue; Cesare Medri; Anne Angelillo-Scherrer; Luca Borradori; S Morteza Seyed Jafari; Susanne Radonjic-Hoesli; Andrew Chan; Robert Hoepner; Ulrike Bacher; Laila-Yasmin Mani; Joseena Mariam Iype; Franziska Suter-Riniker; Cornelia Staehelin; Michael Nagler; Cedric Hirzel Journal: RMD Open Date: 2022-03
Authors: Klaus Hirschbühl; Tina Schaller; Sebastian Dintner; Claudia Wylezich; Bruno Märkl; Rainer Claus; Eva Sipos; Lukas Rentschler; Andrea Maccagno; Bianca Grosser; Elisabeth Kling; Michael Neidig; Thomas Kröncke; Oliver Spring; Georg Braun; Hans Bösmüller; Maximilian Seidl; Irene Esposito; Jessica Pablik; Julia Hilsenbeck; Peter Boor; Martin Beer Journal: Mod Pathol Date: 2022-04-01 Impact factor: 8.209